South San Francisco-based Genentech is nearing a crucial final decision from the FDA on the use of Avastin for breast cancer. An approval, notes the San Francisco Business Times, could boost its revenue by a billion dollars a year. If regulators agree with an advisory committee's recommendation against Avastin, though, the biotech giant stands to lose out big time in the breast cancer market. Genentech currently earns significant revenue from physicians' use of the drug as a therapy for breast cancer--money that is likely to evaporate rapidly with any rejection of its application.
- see this release
- read the story from the San Francisco Business Times
Related Articles:
Genentech's blistering growth starts to cool. Report
Will FDA care about new Avastin study? Report
EU blesses Avastin for broader use. Report
FDA: Avastin lackluster in breast cancer. Report
Avastin re-submitted to FDA. Report